Quick Search 
Drugs of the Future
Register or sign in

Volume 46, Issue 3, March 2021, Pages 183-248
C5a anaphylatoxin chemotactic receptor 1 (C5aR1) antagonist, Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Pease, J.E.
Drugs Fut 2021, 46(3): 183
Summary | Full Text: PDF 
Anti-HER2 monoclonal antibody, Treatment of metastatic HER2-positive breast cancer, Treatment of HER2-positive gastric or gastroesophageal junction cancer.
Hanna, K.S.
Drugs Fut 2021, 46(3): 191
Summary | Full Text: PDF 
Humanized anti-GD2 ganglioside monoclonal antibody, Treatment of high-risk neuroblastoma.
Rickmann, M.
Drugs Fut 2021, 46(3): 197
Summary | Full Text: PDF 
 Exportin-1 (XPO1, CRM1) inhibitors for the management of viral infection.
Heaton, S.M.
Drugs Fut 2021, 46(3): 207
Summary | Full Text: PDF 
 Pipeline on the Move.
Torramade, E., Molas, G.
Drugs Fut 2021, 46(3): 217
Full Text: PDF 
 American Society of Tropical Medicine and Hygiene (ASTMH) – 69th Annual Meeting. Virtual – November 15-19, 2020.
Hodgkinson, L.
Drugs Fut 2021, 46(3): 233
Summary | Full Text: PDF 
 Royal Society of Chemistry's 31st Symposium on Medicinal Chemistry in Eastern England. Virtual – November 26, 2020.
Fernandez Forner, D.F.
Drugs Fut 2021, 46(3): 237
Summary | Full Text: PDF 
 Advances in Genetic Medicine. Highlights from The Society for Medicines Research Online Meeting. Virtual – December 3, 2020.
Alavijeh, M., Brown, P., Butterworth, S., Macdonald, G.
Drugs Fut 2021, 46(3): 243
Summary | Full Text: PDF 

© 2022 Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy